InMed to Identify Cannabinoid Compounds to Treat Orofacial Pain

InMed Pharmaceuticals Inc. (CSE:IN,OTCQB:IMLFF) announced that it has started a program aimed at identifying and evaluating cannabinoid compounds that can be used to treat chronic orofacial pain.

As quoted in the press release:

Initial drug discovery and preclinical development is currently underway in collaboration with members of the Faculty of Pharmaceutical Sciences at the University of British Columbia. The work is being funded by a grant from Mitacs, a leading Canadian organization that accelerates innovative projects through strategic academic and industry collaboration.

Dr. Sazzad Hossain, CSO at InMed, commented:

Pain in the orofacial region is one of the more complex and difficult-to-treat conditions for patients and clinicians. Current treatments are limited in terms of efficacy and are fraught with considerable side effects. Recent advances in cannabinoid pharmacology have renewed hope for these patients with the exciting prospect of safer, more effective cannabis-based treatments. Under this collaboration Inmed will investigate the role of cannabinoid receptors in chronic orofacial pain, including neuropathic pain, muscle pain and arthritis of the jaw joint.

Click here to read the full InMed Pharmaceuticals Inc. (CSE:IN,OTCQB:IMLFF) press release. marketwired